What is the efficacy of lenalidomide (Revlimid) for the treatment of renal cell carcinoma (RCC)?

Updated: Feb 19, 2021
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print
Answer

The immunomodulator lenalidomide (Revlimid), a derivative of thalidomide, inhibits vascular endothelial growth factor (VEGF), stimulates T and natural killer (NK) cells, and inhibits inflammatory cytokines. This agent has been evaluated extensively in hematologic malignancies. In phase II studies of metastatic renal cell carcinoma, lenalidomide demonstrated an antitumor effect in some cases, with disease stabilization or durable partial response. [67, 68]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!